This study hypothesizes that a reduced intensity immunosuppressive preparative regimen will
establish engraftment of donor hematopoietic cells with acceptable early and delayed toxicity
in patients with immune function disorders. A regimen that maximizes host immune suppression
is expected to reduce graft rejection and optimize donor cell engraftment.